August 04, 2018
1 min watch

VIDEO: Early treatment with Iluvien reduces adjunctive treatment burden in DME

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

VANCOUVER, British Columbia — Early introduction of Alimera Sciences’ Iluvien implant (fluocinolone acetonide) in patients with diabetic macular edema will yield the best results in maintenance of vision and stabilization of macular edema, as well as reduction in treatment burden of adjunctive treatments, Sam E. Mansour, MD, said at the American Society of Retina Specialists meeting, where he presented data from the PALADIN and USER studies.